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healthcare budget restrictions leads to the controversial model of procedural jus-
tice. The objective was to describe the characteristics of the current decision-mak-
ing scenario in Brazil using Health Technology Assessment (HTA), its main actors,
consequences and future opportunities.METHODS: A review of HTA regulation in
Brazil and the published literature on the topic was conducted. The Brazilian HTA
model was discussed and strengths and weaknesses highlighted. RESULTS: Over
the years, drug expenditures and healthcare demand have grown exponentially in
Brazil. In 2006, the Brazilian Ministry of Health (MoH) created a HTA process (Reg-
ulation #152). The main objective was to align the dynamics of health technology
decisions with population social needs, epidemiological profile, and healthcare
system financing characteristics. The principal components are a clinical review
and economic analysis of technologies under evaluation. Multiple government
players are involved, but no reference to external involvement. Health technology
decisions take into consideration: a) the relevance/impact of the technologywithin
the system, and b) the safety, effectiveness, and cost-effectiveness of the appraised
technologies. No reference was found to what is considered cost-effective/efficient
for the system. Proposed HTA regulation changes are underway and include: rapid
response, societal engagement (i.e., public consultation of MoH decisions), and
changes in decision determinants (i.e., economic impact to be least important).
CONCLUSIONS: Currently, Brazil holds an informed health technology decision-
making process. However, clear/objective parameters for aiding decisions have not
been described or yet proposed. Uncertainty still remains with regards to efficient
health technology decisions. Current initiatives to improve HTA process are con-
troversial. In the future, HTA could serve as a mediator between constitutional
obligations and current budgetary restrictions in the country.
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OBJECTIVES: 1) Calculate the number of enduring enrollees who entered a state
Medicaid program because of catastrophic injury, and 2) estimate lifetime Medic-
aid costs of the enrollees. METHODS: De-identified administrative data from a
state Medicaid program that included paid fee-for-service claims for medical ser-
vices and prescription medications dated between 2000 and 2005, as well as an
eligibility file listing enrollment periods of recipients, were the data source. The
study is a prospective, longitudinal, historical cohort design. Inpatient hospitaliza-
tion claims with a diagnosis of injury in any of the first three diagnosis fields were
extracted. The study sample comprised recipients less than 65 years old whose
eligibility forMedicaid began on the first of themonth inwhich ahospitalization for
injury occurred. The cohort was followed for the duration of each recipient’s initial
eligibility period. Costs were discounted at 3% and from the perspective of
Medicaid. RESULTS: Eligibility of 2089 recipients started the month they were hos-
pitalized for injury over the study period, a rate of approximately 1.1 per 1000
recipients per year and 6.0 per 1000 new recipients per year. Among the 2089
cohort, 364 (17%) recipients had open-ended eligibility that could last the duration
of life; a majority of whom were over 20 years old. Adults with injury with open-
ended eligibility accounted for approximately 1.5 per 1000 new adult recipients per
year. The estimated lifetime Medicaid cost for medical services and prescription
drugs for a 30-year old male recipient with injury with lifetime eligibility equaled
$76,833. CONCLUSIONS: Catastrophic injury can lead an individual to enter Med-
icaid. One in six entrantsmay require lifetimeMedicaid coverage. In this study, the
rate of lifetime eligibility for Medicaid occurred with low incidence. However, the
cost of injury to the Medicaid program often greatly exceeds the cost of injury
treatment alone.
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OBJECTIVES: The priority of hospital health care results and costs in transitional
countries, needs to avoid non-standardized, unreliable or non-existent data. To
achieve this goal we developed a hospital discharge registry in Argentina
METHODS:AMinimumDischarge Data Set (MDS), designed and extracted from a 1
year output, 2007-2008, of 3 non-profit hospitals with information systems. Cost
and result indicators, harmonized according to WHO and HCUPS (USA) terminol-
ogy, groupers (Clinical Classification Software-CCS single level-SL, 2009) of primary
diagnosis (D1) and procedures (P1), (#CCS [descriptive term]), total costs (CT$)
andmedian per discharge cost ($, 25P-75P-percentiles), in international dollars PPP,
(UN Data: 1Arg$ 1.608 PPP, 2008) were obtained, generating a Pareto ranking of 10
most frequent CCS discharge codes. RESULTS: 58116 discharges with 17125 Dx1
and 9163 Px1 where obtained. The first 10 CCS-SL Dx1 were: #218 [living recently
born] ($ 229, 117-251); #45 [chemotherapy, radiotherapy], ($4705; 1946-8212); #196
[pregnancy and normal delivery], ($ 4.829; 2.958-5.985); # 149 [biliary disorders], ($
5.932; 4.700-9.268); #122 [Pneumonia], ($ 2.193; 1.280- 4.856); #101 [coronary athero-
sclerosis], ($ 22.090; 5.586-38.692); #108 [congestive heart failure, non- hyperten-
sive], ($ 1.918; 989-6.156); # 195 [other complications of delivery], ($ 6.940; 3.971-
8.341); #144 [unspecified neoplasia], ($ 12.975; 4.511-28.960), y #203 [osteoarthritis],
($ 13.490; 8.753- 20.305); comprised 29,4% of discharges, with a CT$ $ 142.852.765
(23,7%). The procedure related CCS of delivery are cesarean section (#134) and other
birth related (#137,#135) represented 6.95% of primary procedures (P1). The most
costly procedure was P1 # ($ 15.834; 4.860-32.168). The first 10 P constitutes a
17,6% of discharges and a 23.9% of procedure CT$. CONCLUSIONS: Transitional
countries can develop this information, but harmonization is required. We ob-
tained 30% of total costs (CT$) and per discharge costs ($) with a Pareto rank. Future
studies need to improve within country generalizability of results.
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OBJECTIVES:Anti-TNF (tumor necrosis factor) drugs are extremely effective for the
treatment of many auto-immune diseases such as rheumatoid arthritis, multiple
sclerosis, and psoriasis. The high price of these medications has a significant im-
pact on the Medicaid budget. The objective was to determine the trends in utiliza-
tion, price and spending for anti-TNF biologics and to analyze the market share
competition between biologics. METHODS: A retrospective, descriptive analysis
was conducted using national summary files from the Medicaid State Drug Utili-
zation Data from 1998 to 2010. Quarterly number of prescriptions and reimburse-
ment data were calculated for the trends analysis. Study drugs included all brand
and generic names of anti-TNF biologics (e.g., abatacept, adalimumab, anakinra,
certolizumab, etanercept, golimumab, infliximab, and rituximab). Market shares
for biologics were quantified and compared between 2006 and 2010. The quarterly
price per prescription was calculated by dividing the total reimbursement by the
total number of prescriptions. RESULTS: The data show an increase in the number
of prescriptions reimbursed over time. Etanercept is the most commonly pre-
scribed biologic in this class, followed by adalimumab. Medicaid has reimbursed
over $1 billion for etanercept, and $500 million for adalimumab. During the period
from 2006Q1 to 2010Q1, etanercept lost 35% of it’s market share. While all other
compounds increased their market share, etanercept lost 40% of its sales market
share. All study biologics have experienced an increase reimbursed price since
initial market entry after one year of entry into market. Older biologics like
etanercept and adalimumab increased over 100% and 60%, respectively. Certoli-
zumab which has only been on the market for two years has increased 15%.
CONCLUSIONS: Biologic medicines represent some of themost complex but costly
products. It will be critical to devise creative methods and incentives to control the
costs of these medicines without stifling the innovation.
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BACKGROUND: Since the establishment of the Greek National Health Care System
in 1983 several reforms have been legally introduced without being implemented.
The recent economic crisis aggravated the performance of the health care system
increasing the inefficiencies and the inequalities. OBJECTIVES: The aim of the
study is to perform a systematic review and critical appraisal of efficiency, quality,
effectiveness and equality of the Greek health care system since the 1980s.
METHODS: A systematic literature review was performed using the following da-
tabases: Center for Reviews and Dissemination (CRD), PubMed, ScienceDirect,
EconLit and EconPapers. The key words used are “Greece”, “health” and “health
care”. The retrieved articles searchedwere 338. Of these 73 paperswere included in
the study analyzing efficiency, equality, and effectiveness of the Greek health care
system over the period 1990-2011. The evolution of public and private health ex-
penditures in conjunction with GDP and health outcome indicators is concerned
using both descriptive and econometric models. RESULTS: The Greek health care
system is fragmented with a mix of public and private activities. Private financing
in Greece is the highest in the European Union with oligopolistic trends in private
hospitals and diagnostic centers. Satisfaction with public services is one of the
lowest in the EU27 countries. Informal payments constitute a significant share
creating distortions in the efficiency of the public sector. Furthermore, informal
payments are regressive imposing a higher economic burden in the lower income
classes. CONCLUSIONS: The systematic review highlights the persistent problems
of the Greek health care systemand signifies the importance of health care reforms
towards greater efficiency and convergence with the rest of the EU countries.
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OBJECTIVES: The global health care environment is in a considerable state of flux
with many national health systems undergoing some degree of reform. Orphan
drugs have historically been funded at a national level through different systems to
the rest of the pharmacopeia. With this in mind, the author set out to assess the
impact of healthcare reform on how orphan drugs are likely to be provided for in
the future.METHODS:This project involved a study of orphan drug provision in the
past and more recently, including both primary and secondary research elements.
Trends in the changing healthcaremarket and specific reformswere considered as
part of a prospective study on the orphan drug landscape. RESULTS: Orphan drug
provision usually utilises a separate infrastructure to manage the allocation of
funding, with this system insulated to a degree from general healthcare reform. In
countries where rare diseases are treated in specific institutions (e.g. Italy) there is
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